Labiotech.eu’s Post

Unlocking the Pharmaceutical Potential of ROW Markets While North America, Europe and Japan have long been the focus of global pharmaceutical expansion, the rapidly growing economies and populations of the Rest of World (ROW) region are impossible to ignore. But what exactly are ROW countries, and why should drug makers pay closer attention? Let's explore: What are ROW Countries? ROW refers to developing and middle-income economies outside the major pharmaceutical hubs - spanning Africa, Latin America, Eastern Europe, the Middle East, and parts of Asia. Key ROW markets include China, India, Brazil, Russia, Turkey, and more. The Allure of ROW ROW's vast, underserved populations, rising incomes, limited competition, and favorable regulatory environments make them alluring targets for pharmaceutical growth. However, navigating the complexities of these diverse markets requires careful planning and strategic partnerships. The Bottom Line As traditional markets become saturated, ROW represents the next frontier for pharmaceutical innovation and expansion. By understanding the unique attributes of these emerging economies, companies can unlock immense new opportunities to reach patients worldwide.

We are headed to Japan! Between October 9 and 11, 360biolabs will be proudly attending #BioJapan2024 as a member of the Australian Mission, organised by the Australian Trade and Investment Commission (Austrade) and supported by Global Victoria.    The oldest biotechnology-focused event in the world, BioJapan fosters knowledge exchange, innovation and collaboration through exhibitions, seminars and its highly regarded partnering program. At this meeting, we will be excited to showcase why Australia is the leading destination for early-phase clinical trials. Our team looks forward to discussing the Australian advantage of speed, cost and quality, highlighting opportunities for attendees to accelerate their clinical studies with our comprehensive bioanalytical services.    If you are venturing to Yokohama for this premier biotechnology event, we encourage you to visit Booth D-60 and connect with members of the Team Australia delegation, to learn more about the benefits of the Australian Advantage in your next study.    For those wishing to learn more about the advanced capabilities and cutting-edge facilities offered by 360biolabs, please reach out to our Senior Business Development Manager, Sharon S. Alternatively, you can secure a one-on-one discussion by emailing bd@360biolabs.com.    We look forward with excitement to forming new strategic alliances, discovering new and emerging technologies, and hearing about the trends shaping the future of biotechnology.  See you in Japan! #BioJapan #BioJapan2024 #biotech #biotechnologyindustry #lifesciences #theaustralianadvantage #clinicaltrials #researchexcellence #bioanalyticallab #biopharmaceutical #teamaustralia #japan #australia

💉 🇧🇷 BRAZILIAN BIOTECH MISSION TO SWITZERLAND COMING UP IN APRIL 2024🇨🇭🔬 Following the success of the first Brazil-Switzerland Biotech Mission last year, Sindusfarma - Industry Syndicate of Pharmaceutical Products and the Brazilian Network for Pharmaceutical Innovation (Rede Brasileira de Inovação Farmacêutica (RBIF)) have announced the opening of registrations for the new biotech business mission from Brazil to Switzerland, from April 22nd to April 25th, 2024. The event will be an enriching journey of exploration and collaboration between both countries in the field of biotechnology. 🔍 BRAZILIAN PARTICIPANTS - WHAT TO EXPECT: Brazilian companies participating in the mission will be able to: ✅ Engage in knowledge exchange, explore business opportunities, and foster cooperation between startups, investors, service providers, and pharmaceutical industries from Brazil and Switzerland. ✅Attend the prestigious #SwissBiotechDay on April 22nd and 23rd, one of Switzerland's premier events in health biotechnology and a global hub of innovation. ✅Take part in business meetings and networking sessions, with access to the Brazilian Stand, offering a platform to showcase your ventures. ✅Dive deeper into the Swiss innovation ecosystem and research centers on April 24th and 25th, with a tailored program designed for practical insights into local operations. 📢 REGISTER NOW: The Brazil-Switzerland Biotech Mission organized by our partners from Sindusfarma and the Brazilian Network for Pharmaceutical Innovation is a unique opportunity to immerse yourself in Switzerland's biotech landscape! Limited spots available. To secure your reservation and learn more, please contact Sindusfarma at rbif@sindusfarma.org.br. 👋 🇨🇭 See you in Switzerland! #BiotechMission #BrazilSwitzerland #Innovation #Biotechnology #Pharmaceuticals #BusinessOpportunities

Wang Yinxiang, Chairman and CEO of Jacobio Pharma, did an exclusive interview with leading Chinese tech&business media 36氪（36kr.com. Discussing the current trend of global BD partnerships in China's biotech sector, he noted that apart from global MNCs, small to mid-size European and US biotech firms are becoming increasingly interested in original scientific breakthroughs and early-stage projects from Chinese biotech companies.These companies are willing to seek incubation pipelines in China that are both economically viable and highly innovative. Speaking about the direction for biotech R&D for 2024, Wang highlighted that conquering challenging targets will play a pivotal role in the competitive landscape of Chinese and global biotech companies. Wang believes that capital "winter" and "spring" is normal and ever-present when looking back at decades of global pharmaceutical development. "Nevertheless, the long-term pursuit of health by humankind is ever-present as well, suggesting a vast space for the development of innovative pharmaceutical companies," he said. #QMportfolio #QMhealthcare #biotech #chinabiotech #36Kr #pharmaleaders #leadership #PharmaceuticalInnovation #Jacobio #HealthcareIndustry

Spain has climbed the R&D ladder in recent years, and has made it to the top as one of the world leaders in the life science industry. 🇪🇸 The country is involved in one out of every three tests that are launched in Europe, and comes second in the world in participating in clinical trials. 🏥 Spain’s leadership in clinical research is rooted in collaborations within the region. 🤝 Labiotech spoke to Raúl Martín-Ruiz, partner at Ysios Capital Partners, about Spain’s rise as a global leader in clinical studies. 📈 Read our latest article to find out more! 👇 https://lnkd.in/dPz-HPDe #Biotech #Clinicaltrials #Spain #Research #RD #Collaboration #Partnerships #Researchanddevelopment AseBio - Asociación Española de Bioempresas | El Pais | FARMAINDUSTRIA | CDTI Innovación - Centro para el Desarrollo Tecnológico y la Innovación | ROVI Pharmaceutical Company | Insud Pharma | Biocat, BioRegion of Catalonia

Last week, President and CEO Christophe Weber met with Prime Minister Alexander De Croo during the World Economic Forum Annual Meeting in Davos.   During the meeting, they discussed Takeda’s significant footprint in Belgium, recognizing our investments and commitment to innovation.   Christophe highlighted the Belgian government's dedication to maintaining the country as a biopharma hub in Europe. The conversation touched on key initiatives, including the R&D bio platform, aimed at sustaining growth and fostering innovation.   With the Belgian EU Presidency underway, there's a fantastic opportunity to elevate a pro-innovation agenda in Europe, and we support Belgium’s commitment to support a thriving ecosystem that supports innovation and resilient supply chains!   Thank you Belgium for shining the spotlight on the biopharmaceutical sector at the World Economic Forum in Davos. We look forward to contributing to the continued success and growth of Belgium as a key player in the biopharmaceutical landscape!   #TakedainBelgium #Innovation #Biopharma #Davos #EU2024 #RDBioPlatform #BusinessLeaders #ElevateInnovation #Biopharma Ministry of Foreign Affairs Belgium

We're honored to be part of the EuropaBio - the European Association for Bioindustries, a working group behind the report entitled 'Impact of the General Pharmaceutical Legislation on Europe's Innovation Ecosystem and Biotechnology Companies'. This comprehensive analysis, conducted in collaboration with EuropaBio, underscores the vital role #biotechnology plays in advancing #healthcare and boosting the EU economy. 🔍 Key Insights: • Biotech innovation is crucial for treating complex diseases and enhancing healthcare quality. • Small biotech innovators are pivotal in translating research into novel therapies. • Proposed changes in the General Pharmaceutical Legislation (GPL) could hinder the progress of new medicines, particularly affecting rare disease treatments and advanced therapies. 🌍 Why This Matters: The EU biotechnology sector is a powerhouse of innovation and economic growth. Maintaining a robust and predictable incentives framework is essential for attracting early-stage investments and sustaining Europe's position as a leader in life sciences. Read the full report on EuropaBio's Website: https://hubs.ly/Q02hzwjS0 Cédric Moreau Claire Skentelbery #Biotech #HealthcareFuture #SofinnovaPartners #EuropaBio #GPLImpact #LifeSciences

Discover why #Poland is emerging as an attractive destination for biomanufacturing outsourcing ▶ EU's Biotech and Biomanufacturing Initiative is boosting competitiveness and #innovation in the region ▶ Poland offers cost-effective services, speed to market, and a convenient #EU location ▶ Strong academic infrastructure with 40+ universities emphasizing biopharma degrees ▶ Ranked 1st in Central Eastern Europe for #bio-pharma graduates ▶ Growing biotech sector with significant increases in #pharmaceutical exports CDMOs like Mabion S.A. demonstrate agility, quality, and cost-effectiveness The article provides valuable insights into the benefits of partnering with Polish #CDMO for #biomanufacturing projects. It's a must-read for #biotech professionals looking to optimize their manufacturing strategies. ⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪⚪ 🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴🔴 Check out the full article to learn more about this emerging hub for biotech innovation and how it could benefit your company's goals: https://lnkd.in/dND63q8U

Biopharma in Belgium appreciation post The OECD recently published an update on biotechnology indicators, and I’m very proud to see Belgium at the top of the list with 35.7%(!) in Biotech R&D added value Seeing Switzerland as a close second raises the question of whether there is a causal relationship between Biotech investment and quality chocolate. As a Belgian, it can be easy to overlook the role our country of 12 million people plays in Life Sciences. But the presence of leading firms Janssen Pharmaceutica, GSK, Sanofi, Pfizer, and Takeda, combined with homegrown innovators like Confo therapeutics, Agomab, and rising star Argenx, is nothing short of spectacular. All this Biotech innovation is no coincidence with world-class incubators and research institutes VIB and Imec. Of course, ONTOFORCE is a proud member of this Life Science ecosystem, supporting innovation and development within the Belgian borders and beyond! #lifesciences #biotech #pharmaceutical

Second Edition, 25-26th of March 2024 What is S-DISCO Days? The International Master of Science in Sustainable Drug Discovery (S-DISCO) is happy to announce the second edition of the Sustainable Drug Discovery Days. Sustainable Drug Discovery (S-DISCO) Days is a two-day international scientific conference designed to enlighten and broaden perspectives on the importance of sustainability in the field of drug discovery. For the year 2024, the conference is scheduled for March 25-26 in Gdansk, Poland. Objective: A response to the need for a sustainable future in drug development, so today’s needs get fulfilled without compromising the ability of future generations to meet their own. Focus Areas: Drug discovery, pharmaceutical sustainability, climate change mitigation, environmental impact, and ensuring equitable access to quality medicines. Program The programme for S-DISCO days 2024 is being finalised and will be released shortly. The first day will feature: • Two influential plenary speakers who are active in the field of sustainable drug discovery; • Speakers from both academia and industry, highlighting emerging sustainability trends in the pharmaceutical workplace. The second day will bring together research groups from the S-DISCO consortium to discuss their pioneering and interdisciplinary research into sustainability across the drug discovery pipeline. It will also include two workshops, giving participants practical skills to translate into their work and studies. Registration Please fill in the following registration form for the S-DISCO Days Conference on 25-26 of March 2024.